Palo Alto, CA—Use of the first-line type 2 diabetes drug metformin was associated with a lower incidence of osteoarthritis, according to a new study that suggests future interventional studies with metformin for preventing OA should be considered.

The article in JAMA Network Open suggests that metformin might be protective against developing OA but that supporting data has been lacking. In response, the study team sought to determine the risk of OA and joint replacement in individuals with type 2 diabetes treated with metformin compared with a sulfonylurea.

For the retrospective cohort study, researchers used claims data from the Optum deidentified Clinformatics Data Mart Database between December 2003 and December 2019. Included were participants aged 40 years or older with at least 1 year of continuous enrollment and type 2 diabetes. Excluded were those with type 1 diabetes or a prior diagnosis of OA, inflammatory arthritis, or joint replacement. Data were analyzed from April to December 2021.

The researchers were focused on incident OA and joint replacement in the two control groups, each of which included 20,937 individuals (mean [SD] age 62.0 [11.5] years; 24,379 [58.2%] males).

In the adjusted analysis, results indicated that the risk of developing OA was reduced by 24% for patients treated with metformin compared with a sulfonylurea (aHR, 0.76; 95% CI, 0.68-0.85; P <.001), although there was no significant difference for risk of joint replacement (aHR, 0.80; 95% CI, 0.50-1.27; P = .34).

In the sensitivity analysis, researchers report that the risk of developing OA remained lower in those treated with metformin compared with a sulfonylurea (aHR, 0.77; 95% CI, 0.65-0.90; P <.001), while the risk of joint replacement remained not statistically significant (aHR, 1.04; 95% CI, 0.60-1.82; P = .89).

“In this cohort study of individuals with diabetes, metformin treatment was associated with a significant reduction in the risk of developing OA compared with sulfonylurea treatment,” the authors concluded. “These results further support preclinical and observational data that suggest metformin may have a protective association against the development of OA; future interventional studies with metformin for the treatment or prevention of OA should be considered.”

Background information in the study points out that metformin is a biguanide derivative that is used as first-line treatment of type 2 diabetes by inhibiting hepatic gluconeogenesis and increasing muscle insulin sensitivity. “Metformin is generally considered safe in most patient populations and is available at a low cost,” the researchers add. “In addition to its primary role in the treatment of diabetes, metformin has been purported to have anti-inflammatory, antiaging, anticancer, pro–weight loss, and immunomodulatory effects.”

They note that animal studies have suggested metformin could be useful for the treatment or prevention of OA, while observational studies in humans “have also largely supported the use of metformin associated with preventing the development of OA or the need for joint replacement.” Those studies mostly focused on the progression of preexisting OA, however, and had other cofounders.

The content contained in this article is for informational purposes only. The content is not intended to be a substitute for professional advice. Reliance on any information provided in this article is solely at your own risk.

 
« Click here to return to Weekly News.